{"title":"他汀类药物的时代——其他类降脂药物还有一席之地吗?","authors":"T. Wascher","doi":"10.1159/000083385","DOIUrl":null,"url":null,"abstract":"Plenty of evidence suggests statins as the first-line therapy for the treatment of lipid disorders. However, further therapeutic options available in the treatment of lipid disorders are fibrates, niacin and cholesterol absorption inhibitors. In the present study, current treatment modalities of lipid disorders are reviewed, and their use was scrutinized based on the available evidence.","PeriodicalId":87985,"journal":{"name":"Heartdrug : excellence in cardiovascular trials","volume":"5 1","pages":"34 - 38"},"PeriodicalIF":0.0000,"publicationDate":"2005-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000083385","citationCount":"1","resultStr":"{\"title\":\"The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?\",\"authors\":\"T. Wascher\",\"doi\":\"10.1159/000083385\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Plenty of evidence suggests statins as the first-line therapy for the treatment of lipid disorders. However, further therapeutic options available in the treatment of lipid disorders are fibrates, niacin and cholesterol absorption inhibitors. In the present study, current treatment modalities of lipid disorders are reviewed, and their use was scrutinized based on the available evidence.\",\"PeriodicalId\":87985,\"journal\":{\"name\":\"Heartdrug : excellence in cardiovascular trials\",\"volume\":\"5 1\",\"pages\":\"34 - 38\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000083385\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heartdrug : excellence in cardiovascular trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000083385\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heartdrug : excellence in cardiovascular trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000083385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?
Plenty of evidence suggests statins as the first-line therapy for the treatment of lipid disorders. However, further therapeutic options available in the treatment of lipid disorders are fibrates, niacin and cholesterol absorption inhibitors. In the present study, current treatment modalities of lipid disorders are reviewed, and their use was scrutinized based on the available evidence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
